Spondyloarthritis & psoriatic arthritis

Sex differences in long-term functional deterioration and permanent disability in spondyloarthritis: a 17-year follow-up from the REGISPON-3 study

RMD OpenPublished Longitudinal observational study

Authors' conclusion

Female patients experienced greater long-term functional deterioration despite similar work disability rates at follow-up.

Study context

Population
Patients with spondyloarthritis (SpA) from the Spanish REGISPONSER registry (baseline 2004–2007), reassessed 17 years later in REGISPON-3 (2021–2024)
Participants
411 patients
Exposure
Female vs male patients with SpA
  • Femalen = 140
  • Malen = 271reference
Outcome
Long-term functional deterioration (BASFI at follow-up, ΔBASFI) and permanent work disability
Follow-up
17 years
Methodological detailsregistry-based, 17-year follow-up, sex-stratified logistic and multivariable linear regression, moderated mediation analysis
  • Registry-based
  • 17-year follow-up
  • Sex-stratified logistic and multivariable linear regression
  • Moderated mediation analysis

Main finding

As reported in the abstract

Functional deterioration (ΔBASFI)

Female

1.47

± 2.81

Male

0.38

± 2.57

P < 0.001

Observational data: associations, not effects.

Further findings

Permanent work disability · 17 years · similar rates

P = 0.31

Predictors of disability and ΔBASFI

Higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Radiology Index (BASRI)-total independently associated with disability in both sexes
Baseline Bath Ankylosing Spondylitis Functional Index (BASFI) and BASDAI predicted ΔBASFI in both sexes; additional predictors in males BASRI-total and occiput-to-wall distance, BASRI-column in females

Indirect effect of bDMARD exposure on ΔBASFI through C reactive protein (CRP) (moderated mediation)

Significant in male but not female patients, with a significant sex interaction

Original publication

Sex differences in long-term functional deterioration and permanent disability in spondyloarthritis: a 17-year follow-up from the REGISPON-3 study. RMD Open. Published 15 July 2026. doi:10.1136/rmdopen-2026-007008

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.